

24|11|2023

FATIMA **SALIH**, BETSY WONDERLY **TRAINOR**, ISABELLE **TONGIO**, DALIA **DAWOUD**

REPORT of the Regulatory/HTA/Payer EAP

Session 7



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.





UNIVERSITÀ di VERONA



University Medical Center Groningen



RAMBAM Health Care Campus



UNIVERSIDAD DE LA RIOJA



NICE National Institute for Health and Care Excellence

Gesundheit Österreich GmbH



ESCMID

EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES



ERS

EUROPEAN RESPIRATORY SOCIETY

every breath counts



Seventh EAP session

1.1. Meeting overview

The seventh session of the VALUE-Dx Expert Advisory Panel (EAP) was held virtually on 04 October 2023. There were seven members of the EAP in attendance.

1.2. Topics and themes discussed

1. VALUE-Dx Progress update:

Update on progress of VALUE-Dx clinical trials since last EAP meeting in March 2023.

2. Presentation from guest speaker; a speaker from the Office of Health Economics in the UK presented two topics:

- Research on patient preferences for diagnostics for antimicrobial resistance
- Transferable exclusivity vouchers as a pull incentive for developing new antimicrobials

3. Sustainability of VALUE-Dx outputs and their useability beyond the project timeline.

4. Reflection on the contribution of the EAP towards the success of VALUE-Dx.

